(Q30878080)

14 November 2017

Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data (English)

1 reference

prostate cancer screening

14 November 2017

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Arnauld Villers

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Monique Roobol

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

E A M Heijnsdijk

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

T M de Carvalho

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

M Zappa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

V Nelen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

M Kwiatkowski

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

A Páez

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

S M Moss

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

T L J Tammela

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

F Recker

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

L Denis

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

S V Carlsson

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

E M Wever

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

C H Bangma

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

F H Schröder

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

J Hugosson

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

H J de Koning

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

13 December 2014

1 reference

Journal of the National Cancer Institute

14 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

366

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

11 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Early detection of prostate cancer: AUA Guideline

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Quality-of-life effects of prostate-specific antigen screening.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

The impact of PLCO control arm contamination on perceived PSA screening efficacy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Prostate-cancer mortality at 11 years of follow-up

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Optimization of PSA screening policies: a comparison of the patient and societal perspectives

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Quality of life three years after diagnosis of localised prostate cancer: population based cohort study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

20-year outcomes following conservative management of clinically localized prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Costs and effects of prostate cancer screening in Sweden--a 15-year follow-up of a randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

A quantitative analysis of the costs and benefits of prostate cancer screening

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Screening for prostate cancer. A decision analytic view

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4296196

Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.

21 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU366

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU366

Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU366

Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU366

Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU366

Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU366

Incidence of prostate cancer after termination of screening in a population-based randomised screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU366

Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU366

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU366

Quality of life and guidelines for PSA screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU366

Economic evaluation of a prostate cancer screening program in France: a decision model

21 January 2018

1 reference

12 December 2020

Life expectancy and the value of early detection

1 reference

12 December 2020

Cancer Detection and Cancer Characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) – Section Rotterdam

1 reference

12 December 2020

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

12 December 2020

Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms

1 reference

12 December 2020

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJU366

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25505238%20AND%20SRC:MED&resulttype=core&format=json